Fundraising FoxTempest Therapeutics
Brisbane, US · 7 known investors
Find your way into Tempest Therapeutics
Sign up to see every warm intro you have to Tempest Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Tempest Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications. Its pipeline includes a dual-target CD19/BCMA CAR structure and a CD7-targeted mRNA lipid nanoparticle CAR-T delivery platform, with lead candidate TPST-4003 planned for trials in myasthenia gravis and multiple sclerosis.
Founders & leadership
Board
Investors · 7
How we know: F-Prime Capital's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Roche Venture Fund's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Funding
SEC filings, press & company announcements$104.2M disclosed across 4 of 5 rounds · 2018–2026
- Undisclosed amountregistered direct offeringNov 2025Source ↗
▶$4.1MraisedJun 2026 · 1 investors · BiotechnologyRule 506(b)
- John David YeeDirector
- Matthew AngelExecutive Officer, Director
- Justin TrojanowskiExecutive Officer
- William Drake RicheyDirector
- Offering amount
- $4.1M
- Amount sold
- $4.1M
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedApr 2026 · 3 investors · BiotechnologyRule 506(b)
- Stephen BradyDirector
- Christine PellizzariDirector
- Matthew AngelExecutive Officer, Director
- Ronit SimantovDirector
- Michael RaabDirector
- Nicholas MaestasExecutive Officer
- Offering amount
- $2M
- Amount sold
- $2M
- Sales commissions
- $105K
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedMay 2022 · 2 investors · BiotechnologyRule 506(b)
- Stephen R. BradyExecutive Officer, Director
- Michael RaabDirector
- Ronit SimantovDirector
- Thomas WoiwodeDirector
- Geoffrey NicholDirector
- Thomas W. DubenskyExecutive Officer, Director
- Christine PellizzariDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$83.2MraisedFeb 2020 · 10 investors · Other Health CareRule 506(b)
- Thomas W. Dubensky, Jr.Executive Officer, Director
- Paul GraysonDirector
- Petpiboon PrasitDirector
- Thomas WoiwodeDirector
- Stella XuDirector
- Robert WeisskoffDirector
- Michael RaabDirector
- Keting ChuDirector
- Offering amount
- $100.2M
- Amount sold
- $83.2M
- Minimum investment
- $1
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Tempest Therapeutics went on to found or lead other companies.
Related companies · 4
Companies working in the same space as Tempest Therapeutics.
Acquisitions · 1
Early investors' stakes continue via these dealsMillendo Therapeutics was a clinical-stage biopharmaceutical company developing treatments for orphan endocrine diseases, including Prader-Willi syndrome and congenital adrenal hyperplasia.
Frequently asked questions
- What does Tempest Therapeutics do?
- Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications. Its pipeline includes a dual-target CD19/BCMA CAR structure and a CD7-targeted mRNA lipid nanoparticle CAR-T delivery platform, with lead candidate TPST-4003 planned for trials in myasthenia gravis and multiple sclerosis.
- Who are Tempest Therapeutics's investors?
- Tempest Therapeutics's investors include F-Prime Capital, LAV, Lilly Asia Ventures, New Enterprise Associates (NEA), Quan Capital, Roche Venture Fund, Versant Ventures.
- How much funding has Tempest Therapeutics raised?
- Tempest Therapeutics has disclosed $104.2M raised across 4 of its 5 known rounds.
- Where is Tempest Therapeutics headquartered?
- Tempest Therapeutics is headquartered in Brisbane, US.